Core Viewpoint - GSK plc is facing a class action lawsuit related to the alleged misleading statements regarding the withdrawal of Zantac from the market and its connection to cancer risks [3][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [3]. - Allegations include that GSK misrepresented the reasons for removing Zantac from the market and claimed there was no evidence linking ranitidine to cancer, despite being aware of the source of NDMA for nearly 40 years [3]. Group 2: Shareholder Actions - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action and can seek lead plaintiff status by the deadline of April 7, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions that inflated GSK's stock price [5].

GSK plc (GSK) announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch for the drug is planned in second-half 2025 under the brand name Blujepa.This approval for Blujepa marks the introduction of a new class of oral antibiotics for uUTIs in nearly 30 years. Per GSK, the drug targets a different part of the bacteria than most existing antibiotics, making it effective against resistant ...

Core Insights - GSK's Nucala has received acceptance for review by the European Medicines Agency for a new indication as an add-on maintenance treatment for COPD with an eosinophilic phenotype [1][5] - Nucala is currently approved for four IL-5-mediated conditions in Europe and is not yet approved for COPD globally [2][3] - If approved, Nucala would be the first biologic with a monthly dosing option for COPD patients in Europe [7] Company Performance - GSK's shares have increased by 16.1% year to date, outperforming the industry average rise of 5.7% [4] - Nucala generated sales of £1.78 billion in 2024, reflecting a 12% year-over-year increase at constant exchange rates, making it a key revenue driver for GSK [7] Clinical Data - The regulatory application for Nucala's COPD indication is based on positive results from the phase III MATINEE study, which demonstrated a significant reduction in the annualized rate of moderate/severe exacerbations compared to placebo [5]

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

GSK (GSK) stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has also been trading above 200 and 50-day moving averages since early March.GSK Stock Underperforms Industry, Sector and S&PImage Source: Zacks Investment ResearchThe main driver of the stock’s recovery in 2025, following the 8.7% dip in 2024, was the increase in its long-term sales outlook for 2031, as annou ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136542&wire=4GSK i ...

NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=136012&from=4 CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATI ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=135482&from=4CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATIO ...

Core Viewpoint - The article discusses the potential of bispecific antibodies to replace CAR-T therapies in the treatment of multiple myeloma, highlighting insights from Dr. Syed Abbas Ali of Johns Hopkins University [3][4][6]. Group 1: Bispecific Antibodies vs. CAR-T Therapies - Dr. Ali emphasizes that bispecific antibodies, particularly those targeting BCMA and CD3, may surpass CAR-T therapies in efficacy and safety, especially as physicians learn to manage toxicity better [6][7]. - The total response rate for Gilead-Arcellx's Anito-cel is reported at 100%, with lower toxicity compared to Johnson & Johnson's Carvykti, which is primarily used for high-risk patients [4][5]. - The safety profile of Anito-cel shows significant advantages, with a median onset of cytokine release syndrome (CRS) at 2 days and a duration of 3 days, compared to Carvykti's 7 days onset and 4 days duration [5]. Group 2: Market Dynamics and Competitive Landscape - The article notes that Blenrep from GlaxoSmithKline faces challenges in regaining market trust after its previous withdrawal, with analysts expressing concerns over its sales growth potential [8]. - Sanofi's Sarclisa is seen as a competitor to Johnson & Johnson's Darzalex, but the latter's ease of use as a monthly subcutaneous injection poses a significant challenge for Sarclisa [9]. - The article highlights the increasing accessibility of blood component apheresis for CAR-T therapy, which has improved patient treatment options [4].

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=134398&wire= ...